CSIMarket Company Name, Ticker, Industry, else..
 
Lipella Pharmaceuticals Inc   (NASDAQ: LIPO)
Other Ticker:  
 
 
Price: $2.3700 $-0.06 -2.469%
Day's High: $2.39 Week Perf: -1.25 %
Day's Low: $ 2.27 30 Day Perf: 5.33 %
Volume (M): 3 52 Wk High: $ 12.00
Volume (M$): $ 8 52 Wk Avg: $3.65
Open: $2.27 52 Wk Low: $1.97



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 1
 Employees 16
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Lipella Pharmaceuticals Inc
Lipella Pharmaceuticals Inc is a pharmaceutical company that specializes in the development, manufacturing, and marketing of innovative drugs and therapies. The company focuses on discovering novel solutions to address unmet medical needs and improve patient outcomes. Lipella Pharmaceuticals aims to create breakthrough treatments in areas such as cancer, autoimmune diseases, and rare disorders. They have a team of dedicated professionals including researchers, scientists, and clinicians who collaborate to bring new drugs from concept to commercialization. With a commitment to scientific excellence and patient care, Lipella Pharmaceuticals strives to make a significant impact on global healthcare.


   Company Address: 7800 Susquehanna St. Pittsburgh 15208 PA
   Company Phone Number: 894-1853   Stock Exchange / Ticker: NASDAQ LIPO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMPH   -6.86%    
AMRX   -3.5%    
ANIP        5.36% 
BPMC   -0.73%    
MRSN        14.79% 
ZYME        6.91% 
• View Complete Report
   



Management Announcement

Lipella Pharmaceuticals: A Promising Drug Pursuit Shrouded in Financial Uncertainty,

Published Mon, Mar 31 2025 3:00 PM UTC

Lipella Pharmaceuticals Faces Financial Challenges Amid Promising Drug DevelopmentIn a recent appearance on the Pharmaverse podcast, Michael Chancellor, co-founder of Lipella Pharmaceuticals, discussed the company?s innovative pursuit of new therapeutic solutions, notably the LP-310, aimed at treating oral lichen planus (OLP). However, while the enthusiasm surrounding Lipe...
Clinical Study

Advancing Therapeutics Lipella Pharmaceuticals Completes First Cohort of LP-310 in Phase 2a Clinical Trial for Oral L...

Published Thu, Nov 21 2024 10:30 AM UTC

Abstract Lipella Pharmaceuticals recently announced the successful completion of the first cohort in its Phase 2a clinical trial investigating LP-310, a novel therapeutic candidate aimed at treating oral lichen planus (OLP). Following the first cohort s analysis, the study will transition to evaluate the next dose group, signaling a pivotal moment in the potential treatmen...
Clinical Study

Lipella Pharmaceuticals Reports Positive Early Tolerability Outcomes in Phase 2a Trial of LP-310 for Oral Lichen Planus

Published Tue, Sep 24 2024 12:01 PM UTC

Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) has announced promising early results from its Phase 2a clinical trial of LP-310, a novel treatment for Oral Lichen Planus (OLP). The study, which primarily focuses on the tolerability of the investigational drug, showed encouraging outcomes, suggesting that LP-310 could hold significant potential for patients suffering from this d...
Clinical Study

Lipella Pharmaceuticals Advances Bladder Imaging at ICICJ Conference Amid Financial Struggles,

Published Wed, Aug 21 2024 9:00 AM UTC

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference Lipella Pharmaceuticals Inc., a leading innovator in urological health, has announced a breakthrough in bladder imaging technology at the International Conference on Innovations in Clinical Journeys (ICICJ). This new technique is poised to revolutionize the way bladder conditions are diagn...
Clinical Study

Lipella Pharmaceuticals Initiates Groundbreaking Phase 2a Clinical Trial for Oral Lichen Planus, Doses Fir...

Published Mon, Aug 12 2024 9:00 AM UTC

Pittsburgh, PA October 2023 Lipella Pharmaceuticals, a pioneering biopharmaceutical company, has successfully dosed the first two patients in its eagerly anticipated Phase 2a clinical trial for the treatment of Oral Lichen Planus (OLP). This significant milestone marks a major step forward in the company s mission to develop effective treatments for this chronic inflamma...






Lipella Pharmaceuticals Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com